CD38 and hematologic disorder: Anomalous CD38 expression in hematologic malignancies correlates with hyper-proliferation of cells, dysregulation of intra- and extracellular metabolic pathways, formation of a tumor permissive microenvironment, and disease progression, thus making CD38 an attractive target for antibody-based therapeutics [16,18,19,20,40].